|
Thursday,
November 16
Pre-Conference Tutorial:
Evolution of Intellectual Property Management and Trends In India –
An Indian Pharmaceutical Industry perspective
(separate registration
required)
7:30 am Pre-Conference Registration and Morning Coffee
8:00 Facilitator’s Welcome and Opening
Remark
India is one of the fastest growing economies in the world. To augment economic growth, India has evolved to understand the importance of Intellectual Property Management (IPM) in a global context and has established a legal framework with supporting laws to establish a Product Patent Regime.
The Pre-Conference Tutorial will focus on the evolution of Intellectual Property Management (IPM) in Indian Pharmaceutical Industry, which can be broadly studied and understood in four phases:
-
Early stages (1950-1970),
-
Process Patent Era (1970-1994),
-
Product Patent, Transition Period, TRIPS Implications (1995-2004)
-
Product Patent Regime, Protection & Implementation (Trends post 2005)
The Workshop attendees will gain an understanding of
-
Patenting system in India
-
Patent protection and execution of Inventors’ rights in India
-
IPM experience of an Indian Company, an internal perspective
-
IPM viewpoints of an Indian Company as a Collaborator/Outsourcing partner of Global Innovator Pharma/Biotech, a case study
| About your tutorial leaders: |
|
|
Dr. G. Om Reddy, Chief Executive Officer, R&D, Orchid Research Laboratories Ltd
Dr. G. Om Reddy, MSc., Ph.D., is CEO and Executive Director of Orchid Research Laboratories Limited
(ORLL), the New Drug Discovery Entity of OCPL. ‘Om’ is associated with Indian Chemical and Pharmaceutical Industry for the past 30 years in areas of Synthetic Organic Chemistry, Analytical Chemistry, Intellectual Property Management, New Product Development, Research Management and General Administration. He is a member of the “Royal Society of Chemistry” and other Chemical societies in US, Japan and India. He was associated with a research contract with US Bureau of Mines, Dept. of Interior, U.S. Govt at
Pittsburg, USA for two years. He is author/co-author in more than 51 referred international journals and inventor/co-inventor of more than 120 patents. |
|
|
|
|
Dr. C. B.
Rao, Deputy Managing Director, Orchid Chemicals & Pharmaceuticals Ltd
Dr. C. B. Rao, M.Tech, Ph.D., is Deputy Managing Director of Orchid Chemicals and Pharmaceuticals
(OCPL - Group Company). Dr Rao is associated for the past 32 years in the areas of Strategic and corporate planning, Legal Liaison, human resource development, information technology, production planning, industrial engineering and general management. He has been associated with various industries namely - Pharmaceuticals, Banking and Automobiles. He is widely traveled and an invited speaker in several industrial and business forums. He is Recipient of Times Research Foundation Award for two years and has 35 papers in referred Research publications (of which 2 papers are in book form). |
|
|
|
|
Dr. Prasad S.
Patala, DGM, Business Development, Orchid Research Laboratories Ltd
Dr Prasad S Patala, BVSc (vet) MS, Po.Doc (Cornell), MS (IT), MBA. ‘Prasad’ S Patala is Deputy General Manager, R & D - Business development and works closely with the Corporate Strategy Group. He is a strategic decision maker and a macro-level operational facilitator utilizing diverse global education/ experience in the US, EU and Indian Pharmaceutical, Biotech and Animal Health Industry for the past 15 years. He has been associated with Business Development, Marketing, Customer/Client, Global Product/Project and Research Management besides short term Management and IT consulting. As a technocrat, His product development/licensing activities include Human and Animal Health Diagnostics/Biopharmaceuticals in infectious agents and cancer. He has been an interim Post-Doctoral faculty at Cornell University, USA and was awarded an ‘Invention patent’ for his graduate research work at
UMCP, USA |
About Orchid:
Orchid Research Laboratories Limited (ORLL) is a New Drug Discovery and development and is focussed in four therapeutic areas to present leads upto pre-clinical stage and/or Phase 1/2. ORLL is equipped with sophisticated chemical and analytical equipment, supported by a good technical infrastructure including an Indian GLP accredited Pre-clinical facility, which is as per global standards.
Orchid aims to become a “partner of choice” to global pharma companies in New Chemical Entity (NCE) Discovery and Development and related R&D services namely custom synthesis, chemical development (CMC), analytical testing and Pre-Clinical ADME/tox within the purview of effective IPR policy.
As a business model, ORLL pursues a co-development and/or out-licensing model, besides rendering R & D contract services on a FTE or quote basis.
11:30 Close of Pre-Conference Tutorial
|
